Physician profile
Amber B Catlin
NPI 1912351701
$2,724.95
in general payments reported to CMS, 2019-2025
34 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $23.51 · 2023: $144 · 2024: $603 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,463.59 |
| Education | $225.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $328.09 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pfizer INC. | $290.98 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $290.91 | 2023-2025 | |
| Seagen INC. | $199.98 | 2023-2024 | |
| Pharmaessentia USA Corporation | $139.08 | 2025 | Besremi |
| Daiichi Sankyo INC. | $136.98 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $131.77 | 2024-2025 | Erleada, Rybrevant, Akeega |
| Astrazeneca Pharmaceuticals LP | $113.87 | 2024-2025 | Enhertu, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $98.82 | 2021-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $84.82 | 2025 | Onivyde |
| Incyte Corporation | $77.53 | 2024-2025 | Jakafi |
| Puma Biotechnology, INC. | $69.08 | 2025 | |
| Gilead Sciences, INC. | $68.98 | 2025 | Trodelvy |
| Lilly USA, LLC | $67.89 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $66.62 | 2025 | Iclusig, Fruzaqla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $55.49 | 2025 | Phesgo, Tecentriq |
| Array Biopharma INC | $50.04 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Adc Therapeutics America, INC. | $46.36 | 2025 | |
| Astellas Pharma US INC | $39.92 | 2022-2025 | Xtandi |
| Genzyme Corporation | $33.96 | 2025 | |
| Jazz Pharmaceuticals INC. | $32.78 | 2025 | |
| Rigel Pharmaceuticals, INC. | $30.07 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Alnylam Pharmaceuticals INC. | $29.26 | 2025 | Givlaari |
| Nuvation Bio INC. | $29.10 | 2025 | Ibtrozi |
| Caris Mpi, INC. | $26.23 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $24.79 | 2024 | Orserdu |
| Abbvie INC. | $24.75 | 2025 | |
| Glaxosmithkline, LLC. | $23.64 | 2025 | Jemperli, Zejula |
| Agios Pharmaceuticals, INC. | $23.54 | 2025 | Pyrukynd |
| Amgen INC. | $21.21 | 2024 | Evenity, Prolia |
| Foundation Medicine, INC. | $19.85 | 2023 | Foundationone Liquid Cdx |
| Servier Pharmaceuticals LLC | $18.46 | 2024 | |
| Beigene USA, INC. | $16.06 | 2024 | Brukinsa |
| Immunocore Limited | $14.04 | 2025 | Kimmtrak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Catlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.